TY - JOUR
T1 - Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥70years)
AU - Basso, Umberto
AU - Roma, Anna
AU - Brunello, Antonella
AU - Falci, Cristina
AU - Fiduccia, Pasquale
AU - Banzato, Alberto
AU - Bononi, Antonio
AU - Gusella, Milena
AU - Vamvakas, Lampros
AU - Zagonel, Vittorina
AU - Monfardini, Silvio
PY - 2013/10
Y1 - 2013/10
N2 - Background: We conducted a multicenter prospective trial to assess tolerability and activity of pegylated liposomal doxorubicin (PLD) in women ≥. 70. years with locally-advanced or metastatic breast cancer. Patients and Methods: All patients underwent Multidimensional Geriatric Assessment (MGA). Frail patients were excluded. Normal cardiac function was required for inclusion. A bi-weekly schedule of PLD at 20. mg/mq was adopted. Results: Thirty-two patients were enrolled with a median age of 78years, 78.1% with visceral involvement, and 37.6% previously treated with chemotherapy for advanced disease. A mean of 7.8cycles were delivered (range 1 to 20), with a median cumulative dose intensity of 8.9mg/m2/week. Grade 3-4 toxicities were anemia (6.3%), palmar-plantar erythrodysesthesia (6.3%), mucositis (6.3%), infection (3.1%), and pulmonary embolism (3.1%). No cardiac events were registered. Causes of treatment interruption were maximal response (15.6%), progression (40.6%), refusal/loss to follow-up (28.1%), toxicities (9.4%), or other (6.3%). Response was obtained in 33.3% of 27 evaluable patients; median time to progression (TTP) was 10.3months. MGA status (vulnerable vs. fit) did not have an impact on response, progression, and toxicity. Conclusions: Bi-weekly PLD is well tolerated in both fit and vulnerable patients, with an apparently fairly good response rate and TTP (possibly biased by subsequent endocrine therapy and loss to follow-up). Close observation of patients is recommended in order to avoid early refusal/loss to follow-up.
AB - Background: We conducted a multicenter prospective trial to assess tolerability and activity of pegylated liposomal doxorubicin (PLD) in women ≥. 70. years with locally-advanced or metastatic breast cancer. Patients and Methods: All patients underwent Multidimensional Geriatric Assessment (MGA). Frail patients were excluded. Normal cardiac function was required for inclusion. A bi-weekly schedule of PLD at 20. mg/mq was adopted. Results: Thirty-two patients were enrolled with a median age of 78years, 78.1% with visceral involvement, and 37.6% previously treated with chemotherapy for advanced disease. A mean of 7.8cycles were delivered (range 1 to 20), with a median cumulative dose intensity of 8.9mg/m2/week. Grade 3-4 toxicities were anemia (6.3%), palmar-plantar erythrodysesthesia (6.3%), mucositis (6.3%), infection (3.1%), and pulmonary embolism (3.1%). No cardiac events were registered. Causes of treatment interruption were maximal response (15.6%), progression (40.6%), refusal/loss to follow-up (28.1%), toxicities (9.4%), or other (6.3%). Response was obtained in 33.3% of 27 evaluable patients; median time to progression (TTP) was 10.3months. MGA status (vulnerable vs. fit) did not have an impact on response, progression, and toxicity. Conclusions: Bi-weekly PLD is well tolerated in both fit and vulnerable patients, with an apparently fairly good response rate and TTP (possibly biased by subsequent endocrine therapy and loss to follow-up). Close observation of patients is recommended in order to avoid early refusal/loss to follow-up.
KW - Anthracyclines
KW - Breast cancer
KW - Chemotherapy
KW - Elderly
KW - Liposomal doxorubicin
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=84884977834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884977834&partnerID=8YFLogxK
U2 - 10.1016/j.jgo.2013.07.004
DO - 10.1016/j.jgo.2013.07.004
M3 - Article
C2 - 24472477
AN - SCOPUS:84884977834
VL - 4
SP - 340
EP - 345
JO - Journal of Geriatric Oncology
JF - Journal of Geriatric Oncology
SN - 1879-4068
IS - 4
ER -